TriSalus Life Sciences, Inc. (TLSI)
NASDAQ: TLSI · Real-Time Price · USD
3.630
-0.270 (-6.92%)
At close: Oct 16, 2026, 4:00 PM EDT
3.660
+0.030 (0.83%)
After-hours: Oct 16, 2026, 7:30 PM EDT
TriSalus Life Sciences Revenue
TriSalus Life Sciences had revenue of $11.41M in the quarter ending June 30, 2026, with 1.73% growth. This brings the company's revenue in the last twelve months to $45.08M, up 25.25% year-over-year. In the year 2025, TriSalus Life Sciences had annual revenue of $45.15M with 53.41% growth. That makes TriSalus Life Sciences the 28,675th largest company in the world by revenue and 3,852nd in the United States.
Revenue (ttm)
$45.08M
Revenue Growth
+25.25%
P/S Ratio
4.96
Revenue / Employee
$441,931
Employees
102
Market Cap
223.52M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 45.15M | 15.72M | 53.41% |
| Dec 31, 2024 | 29.43M | 10.92M | 58.99% |
| Dec 31, 2023 | 18.51M | 6.11M | 49.31% |
| Dec 31, 2022 | 12.40M | 4.00M | 47.58% |
| Dec 31, 2021 | 8.40M | 2.97M | 54.60% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Inogen | 354.30M |
| Treace Medical Concepts | 205.31M |
| InfuSystem Holdings | 143.34M |
| RxSight | 127.58M |
| Standard BioTools | 84.60M |
| Electromed | 73.78M |
| Mobia Medical | 45.28M |
| ClearPoint Neuro | 42.28M |
TLSI News
- 25 days ago - TriSalus Life Sciences price target raised to $12 from $11 at H.C. Wainwright - TheFly
- 26 days ago - TriSalus Life Sciences receives FDA clearance for TriNav Advance - TheFly
- 26 days ago - TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization - Business Wire
- 4 weeks ago - TriSalus Life Sciences Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 5 weeks ago - TriSalus Life Sciences initiated with a Buy at H.C. Wainwright - TheFly
- 6 weeks ago - TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference - Business Wire
- 2 months ago - TriSalus Life Sciences Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts
- 2 months ago - TriSalus Life Sciences reports Q2 EPS (16c), consensus (16c) - TheFly